Vascular toxicity of chemotherapeutic agents

Current Vascular Pharmacology

Volumn 8, Issue 5, 2010, Pages 692-700

  López Miranda, Visitación ^a   Herradón, Esperanza ^a   González, Cristina ^a   Martín, Ma Isabel ^a  

^a UNIVERSIDAD REY JUAN CARLOS   (Spain)

Author keywords

Chemotherapeutic drugs; Vascular toxicity

Indexed keywords

ALTRETAMINE; ANTINEOPLASTIC AGENT; ARABINOSIDE; AZATHIOPRINE; BUSULFAN; CARBOPLATIN; CARMUSTINE; CHLORAMBUCIL; CISPLATIN; CLADRIBINE; CYCLOPHOSPHAMIDE; DACARBAZINE; FLOXURIDINE; FLUDARABINE; IFOSFAMIDE; LOMUSTINE; MELPHALAN; MERCAPTOPURINE; MITOZOLOMIDE; MUSTARD GAS; NEDAPLATIN; OXALIPLATIN; PENTOSTATIN; PROCARBAZINE; SATRAPLATIN; TEMOZOLOMIDE; TIOGUANINE; TRIPLATIN TETRANITRATE; UNINDEXED DRUG; URAMUSTINE;

ADVANCED CANCER; AGRANULOCYTOSIS; ALOPECIA; AMENORRHEA; APLASTIC ANEMIA; BLEEDING; BLOOD CELL COUNT; CANCER CHEMOTHERAPY; CARDIOMYOPATHY; CELL CYCLE; COGNITIVE DEFECT; CONGESTIVE HEART FAILURE; DERMATITIS; DIARRHEA; DRUG TOXICITY; FATIGUE; GRANULOCYTOPENIA; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HUMAN; HUMORAL IMMUNITY; HYPERURICEMIA; INFECTION; INTERSTITIAL LUNG DISEASE; LYMPHOCYTOPENIA; LYMPHOMA; MOUTH INFECTION; MYOCARDITIS; NAUSEA AND VOMITING; NEPHROTOXICITY; NONHUMAN; OLIGOSPERMIA; OTOTOXICITY; PERICARDITIS; REVIEW; SEVERE CONGENITAL NEUTROPENIA; STOMATITIS; SYSTOLIC BLOOD PRESSURE; THROMBOCYTOPENIA; VASCULAR DISEASE; XEROSTOMIA; ANIMAL; ARTICLE; AUTONOMIC NERVOUS SYSTEM; BLOOD VESSEL; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; DRUG MONITORING; NEOPLASM; VASCULAR ENDOTHELIUM;

ANIMALS; ANTINEOPLASTIC AGENTS; AUTONOMIC NERVOUS SYSTEM; BLOOD VESSELS; DRUG MONITORING; ENDOTHELIUM, VASCULAR; HUMANS; NEOPLASMS; VASCULAR DISEASES;

EID: 84863788151     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016110792007012     Document Type: Review

References (120)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin 2007; 57: 43-66.
2. www.worldcancercongress.org. International Union Against Cancer.
3. Tripathi KD. In: Essentials of Medical Pharmacology. New Delhi, Jaypee Brothers Medical Publishers (P) Ltd, 2008; pp. 820-844.
4. Zinzani PL. Primary gastric diffuse large-cell lymphoma. Leuk Lymphoma 2006; 47: 1201-2.
5. Jones RL, Ewer MS. Cardiac and cardiovascular toxicity of nonanthracycline anticáncer drugs. Expert Rev Anticancer Ther 2006; 6: 1249-1269.
6. Singal PK, Iliskovic N, Li T, Kumar D. Adriamycin cardiomyopathy: pathophysiology and prevention. FASEB J 1997; 11: 931-936.
7. Jones RL, Swanton C, Ewer MS. Anthracycline cardiotoxicity. Expert Opin Drug Saf 2006; 5: 791-809.
8. Ricciardi S, Tomao S, de Marinis F. Toxicity of targeted therapy in non-small-cell lung cancer management. Clin Lung Cancer 2009; 10: 28-35.
9. Haugnes HS, Aass N, Fossa SD, et al. Predicted cardiovascular mortality and reported cardiovascular morbidity in testicular cancer survivors. J Cancer Surviv 2008; 2: 128-137.
10. Ishioka J, Fujii Y, Kageyama Y, Fukuda H, Higashi Y, Kihara K. Cardiovascular events in survivors of high-dose chemotherapy for germ cell tumors. Int J Urol 2008; 15: 642-645.
11. Gospodarowicz M. Testicular cancer patients: considerations in long-term follow-up. Hematol Oncol Clin North Am 2008; 22: 245-255.
12. Vaughn DJ, Palmer SC, Carver JR, Jacobs LA, Mohler ER. Cardiovascular risk in long-term survivors of testicular cancer. Cancer 2008; 112: 1949-1953.
13. Calvo-Romero JM, Fernández-Soria-Pantoja R, Arrebola-Garcia JD, Gil-Cubero M. Ischemic heart disease associated with vincristine and doxorubicin chemotherapy. Ann Pharmacother 2001; 35: 1403-1405.
14. Gordon MS, Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology 2005; 69: 25-33.
15. Drímal J, Zúrová-Nedelcevová J, Knezl V, Sotníková R, Navarová J. Cardiovascular toxicity of the first line cancer chemotherapeutic agents: doxorubicin, cyclophosphamide, streptozotocin and bevacizumab. Neuro Endocrinol Lett 2006; 27: 176-179.
16. Wu S, Ko YS, Teng MS, et al. Adriamycin-induced cardiomyocyte and endothelial cell apoptosis: in vitro and in vivo studies. J Mol Cell Cardiol 2002; 34: 1595-1607.
17. Cheng CF, Juan SH, Chen JJ, et al. Pravastatin attenuates carboplatin-induced cardiotoxicity via inhibition of oxidative stress associated apoptosis. Apoptosis 2008; 13: 883-894.
18. Platel D, Pouna P, Bonoron-Adèle S, Robert J. Preclinical evaluation of the cardiotoxicity of taxane-anthracycline combinations using the model of isolated perfused rat heart. Toxicol Appl Pharmacol 2000; 163: 135-140.
19. Pouna P, Bonoron-Adèle S, Gouverneur G, Tariosse L, Besse P, Robert J. Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention. Br J Pharmacol 1996; 117: 1593-1599.
20. Hirano S, Wakazono K, Agata N, Iguchi H, Tone H. Comparison of cardiotoxicity of pirarubicin, epirubicin and doxorubicin in the rat. Drugs Exp Clin Res 1994; 20:153-160.
21. Al-Majed AA, Sayed-Ahmed MM, Al-Yahya AA, Aleisa AM, Al-Rejaie SS, Al-Shabanah OA. Propionyl-L-carnitine prevents the progression of cisplatin-induced cardiomyopathy in a carnitinedepleted rat model. Pharmacol Res 2006; 53: 278-286.
22. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 2000; 22: 263-302.
23. Hirsch J. An anniversary for cancer chemotherapy. JAMA 2006; 296: 1518-1520.
24. Goodman LS, Wintrobe MM, Dameshek W, Goodman MJ, Gilman A, McLennan MT. Nitrogen mustard therapy. JAMA 1946; 132: 26-32.
25. Goodman LS, Wintrobe MM, Dameshek W, Goodman MJ, Gilman A, McLennan MT. Landmark article Sept. 21, 1946: Nitrogen mustard therapy. Use of methyl-bis(beta-chloroethyl)amine hydrochloride and tris(beta-chloroethyl)amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. By Louis S. Goodman, Maxwell M. Wintrobe, William Dameshek, Morton J. Goodman, Alfred Gilman and Margaret T. McLennan. JAMA 1984; 251: 2255-2261.
26. Joensuu H. Systemic chemotherapy for cancer: from weapon to treatment. Lancet Oncol 2008; 9: 304.
27. Chabner BA, Amrein PC, Druker BJ, et al. Fármacos antineoplásicos. In: Goodman and Gilman. Las bases farmacológicas de la terapéutica Ed. México D.F. McGraw-Hill Interamericana. 2006; pp. 1315-1403.
28. Viale PH, Yamamoto DS. Cardiovascular toxicity associated with cancer treatment. Clin J Oncol Nurs 2008; 12: 627-638.
29. Levine EG, Bloomfield CD. Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. Semin Oncol 1992; 19: 47-84.
30. Hijiya N, Hudson MM, Lensing S, et al. Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. JAMA 2007; 297: 1207-1215.
31. Tannock IF, Ahles TA, Ganz PA, Van Dam FS. Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol 2004; 22: 2233-2239.
32. Sleijfer S. Bleomycin-induced pneumonitis. Chest 2001; 120: 617-624.
33. Zhang B, Ramesh G, Norbury CC, Reeves WB. Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor-alpha produced by renal parenchymal cells. Kidney Int 2007; 72: 37-44.
34. Rademaker-Lakhai JM, Crul M, Zuur L, et al. Relationship between cisplatin administration and the development of ototoxicity. J Clin Oncol 2006; 24: 918-924.
35. Bertoli P, Lassalle M, Mercier G, et al. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol 2004; 26: 649-655.
36. Locatelli R, Rossi F. Incidence and pathogenesis of tumor lysis syndrome. Contrib Nephrol 2005; 147: 61-81.
37. Windebank AJ, Grisold W. Chemotherapy-induce neuropathy. J Peripher Nerv Syst 2008; 13: 27-46.
38. Murillo JR, Cox JE, Oholendt MS. An overview of chemotherapyinduced peripheral neuropathy. J Pharm Pract 2008; 21: 138-145.
39. Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol 2002; 249: 9-17.
40. Ocean AJ, Vahdat LT. Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies. Support Care Cancer 2004; 12: 619-625.
41. Hansen SW. Autonomic neuropathy after treatment with cisplatin, vinblastine, and bleomycin for germ cell cancer. Br Med J 1990; 300: 511-512.
42. Chanan-Khan A, Srinivasan S, Czuczman MS. Prevention and management of cardiotoxicity from antineoplastic therapy. J Support Oncol 2004; 2: 251-256.
43. Yamac D, Elmas C, Ozoul C, Keskil Z, Dursun A. Ultrastructural damage in vascular endothelium in rats treated with paclitaxel and doxorubicin. Ultrastruct Pathol 2006; 30: 103-110.
44. Sudharsan PT, Mythili Y, Selvakumar E, Varalakshmi P. Lupeol and its ester exhibit protective role against cyclophosphamideinduced cardiac mitochondrial toxicity. J Cardiovasc Pharmacol 2006; 47: 205-210.
45. Falanga A. The incidence and risk of venous thromboembolism associated with cancer and nonsurgical cancer treatment. Cancer Invest 2009; 27: 105-115.
46. Grisold W, Oberndorfer S, Struhal W. Stroke and cancer: a review. Acta Neurol Scand 2009; 119: 1-16.
47. Haugnes HS, Aass N, Fosså SD, et al. Components of the metabolic syndrome in long-term survivors of testicular cancer. Ann Oncol 2007; 18: 241-248.
48. Liavaag AH, Tonstad S, Pripp AH, Tropé C, Dørum A. Prevalence and determinants of metabolic syndrome and elevated Framingham risk score in epithelial ovarian cancer survivors: a controlled observational study. Int J Gynecol Cancer 2009; 19: 634-640.
49. Stava CJ, Jimenez C, Vassilopoulou-Sellin R. Endocrine sequelae of cancer and cancer treatments. J Cancer Surviv 2007; 1: 261-274.
50. Nuver J, Smit AJ, Sleijfer DT, et al. Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. Eur J Cancer 2004; 40: 701-706.
51. Nuver J, Smit AJ, Wolffenbuttel BH, et al. The metabolic syndrome and disturbance in hormone levels in long-term survivors of disseminated testicular cancer. J Clin Oncol 2005; 23: 3718-325.
52. Sagstuen H, Aass N, Fossa SD, et al. Blood pressure and body mass index in longterm survivors of testicular cancer. J Clin Oncol 2005; 23: 4980-4990.
53. Ochodnicky P, Henning RH, Buikema H, et al. Renal endothelial function and blood flow predict the individual susceptibility to adriamycin-induced renal damage. Nephrol Dial Transplant 2009; 24: 413-420.
54. Kotamraju S, Konorev EA, Joseph J, Kalyanaraman BJ. Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen. Role of reactive oxygen and nitrogen species. Biol Chem 2000; 275: 33585-33592.
55. Dalske HF, Hardy K. Effect of low-dose doxorubicin on calcium content and norepinephrine response in rat aorta. Eur J Cancer Clin Oncol 1988; 24: 979-983.
56. Huddart RA, Norman A, Shahidi M, et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 2003; 21: 1513-1523.
57. van den Belt-Dusebout AW, Nuver J, de Wit R, et al. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2006; 24: 467-475.
58. Dietrich J, Marienhagen J, Schalke B, Bogdahn U, Schlachetzki F. Vascular neurotoxicity following chemotherapy with cisplatin, ifosfamide, and etoposide. Ann Pharmacother 2004; 38: 242-246.
59. Serrano-Castro PJ, Guardado-Santervás P, Olivares-Romero J. Ischemic stroke following cisplatin and 5-fluorouracil therapy: a transcranial Doppler study. Eur Neurol 2000; 44: 63-64.
60. Periard D, Boulanger CM, Eyer S, et al. Are circulating endothelialderived and platelet-derived microparticles a pathogenic factor in the cisplatin-induced stroke? Stroke 2007; 38: 1636-1638.
61. Oh JH, Baum DD, Pham S, et al. Long-term complications of platinum-based chemotherapy in testicular cancer survivors. Med Oncol 2007; 24: 175-181.
62. Wolf MB, Baynes JW. The anti-cancer drug, doxorubicin, causes oxidant stress-induced endothelial dysfunction. Biochim Biophys Acta 2006; 1760: 267-271.
63. Chow AY, Chin C, Dahl G, Rosenthal DN. Anthracyclines cause endothelial injury in pediatric cancer patients: a pilot study. J Clin Oncol 2006; 24: 925-928.
64. De Vos FY, Willemse PH, de Vries EG, Gietema JA. Endothelial cell effects of cytotoxics: balance between desired and unwanted effects. Cancer Treat Rev 2004; 30: 495-513.
65. Baluna R, Rizo J, Gordon BE, Ghetie V, Vitetta ES. Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome. Proc Natl Acad Sci USA 1999; 96: 3957-3962.
66. Wethal T, Kjekshus J, Røislien J, et al. Treatment-related differences in cardiovascular risk factors in long-term survivors of testicular cancer. J Cancer Surviv 2007; 1: 8-16.
67. Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008; 300: 2277-2285.
68. Hobson AR, McKenzie DB, Kunadian V, et al. Malignancy: an unrecognized risk factor for coronary stent thrombosis? J Invasive Cardiol 2008; 20: 120-123.
69. Levine MN. Adjuvant therapy and thrombosis: how to avoid the problem? Breast 2007; 16: 169-174.
70. Cunningham MS, Preston RJ, O'Donnell JS. Does antithrombotic herapy improve survival in cancer patients? Blood Rev 2009; 23: 129-135.
71. Akl EA, Kamath G, Yosuico V, et al. Thromboprophylaxis for patients with cancer and central venous catheters: a systematic review and a meta-analysis. Cancer 2008; 112: 2483-2492.
72. Filippatos TD, Liberopoulos EN, Pavlidis N, Elisaf MS, Mikhailidis DP. Effects of hormonal treatment on lipids in patients with cancer. Cancer Treat Rev 2009; 35: 175-184.
73. Yüce A, Ateahin A, Ceribai AO, Aksakal M. Ellagic acid prevents cisplatin-induced oxidative stress in liver and heart tissue of rats. Basic Clin Pharmacol Toxicol 2007; 101: 345-349.
74. Hernandez-Esquivel L, Marin-Hernandez A, Pavón N, Carvajal K, Moreno-Sanchez R. Cardiotoxicity of copper-based antineoplastic drugs casiopeinas is related to inhibition of energy metabolism. Toxicol Appl Pharmacol 2006; 212: 79-88.
75. Cigremis Y, Parlakpinar H, Polat A, et al. Beneficial role of aminoguanidine on acute cardiomyopathy related to doxorubicintreatment. Mol Cell Biochem 2006; 285: 149-154.
76. Oz E, Erba D, Surucu HS, Duzgun E. Prevention of doxorubicininduced cardiotoxicity by melatonin. Mol Cell Biochem 2006; 282: 7-31.
77. Herradón E, González C, Martín MI, López-Miranda V. Endothelial dysfunction caused by chronic cisplatin treatment is improved the synthetic cannabinoid, Win55,212-2. Hypertension 2008; 52: 768.
78. Freeman R. Autonomic peripheral neuropathy. Lancet 2005; 365: 1259-1270.
79. Scigliano G, Ronchetti G, Girotti F, Musicco M. Sympathetic modulation by levodopa reduces vascular risk factors in Parkinson disease. Parkinsonism Relat Disord 2009; 15: 138-143.
80. Ewing DJ, Campbell IW, Clarke BF. Heart rate changes in diabetes mellitus. Lancet 1981; 1: 183-186.
81. Low PA, Walsh JC, Huang CY, McLeod JG. The sympathetic nervous system in diabetic neuropathy: a clinical and pathological study. Brain 1975; 98: 341-356.
82. Langer A, Freeman MR, Josse RG, Steiner G, Armstrong PW. Detection of silent myocardial ischemia in diabetes mellitus. Am J Cardiol 1991; 67: 1073-1078.
83. Burgos LG, Ebert TJ, Asiddao C, et al. Increased intraoperative cardiovascular morbidity in diabetics with autonomic neuropathy. Anesthesiology 1989; 70: 591-597.
84. Veglio M, Sivieri R, Chinaglia A, Scaglione L, Cavallo-Perin P. QT interval prolongation and mortality in type 1 diabetic patients: a 5-year cohort prospective study. Diabetes Care 2000; 23: 1381-1383.
85. Stevens MJ, Raffel DM, Allman KC, et al. cardiac sympathetic dysinnervation in diabetes: implications for enhanced cardiovascular risk. Circulation 1998; 98: 961-968.
86. Sioka C, Kyritsis AP. Central and peripheral nervous system toxicity of common chemotherapeutic agents. Cancer Chemother Pharmacol 2009; 63: 761-767.
87. Roca E, Bruera E, Politi PM, et al. Vinca alkaloid-induced cardiovascular autonomic neuropathy. Cancer Treat Rep 1985; 69: 149-151.
88. Weissman-Fogel I, Dashkovsky A, Rogowski Z, Yarnitsky D. An animal model of chemotherapy-induced vagal neuropathy. Muscle Nerve 2008; 38: 1634-1637.
89. Rosenfeld CS, Broder LE. Cisplatin-induced autonomic neuropathy. Cancer Treat Rep 1984; 68: 659-660.
90. Turlapaty PD, Altura BM. Magnesium deficiency produces spasms of coronary arteries: relationship to etiology of sudden death ischemic heart disease. Science 1980; 208: 198-200.
91. Vassilomanolakis M, Tsoussis S, Efremidis A. Long lasting, grade IV, orthostatic hypotension after a single cycle combination chemotherapy with paclitaxel and cisplatin. Eur J Cancer 1998; 34: 1295.
92. Jerian SM, Sarosy GA, Link CJ Jr, Fingert HJ, Reed E, Kohn EC. Incapacitating autonomic neuropathy precipitated by taxol. Gynecol Oncol 1993; 51: 277-280.
93. Vera G, Chiarlone A, Cabezos PA, Pascual D, Martín MI, Abalo R. WIN 55,212-2 prevents mechanical allodynia but not alterations in feeding behaviour induced by chronic cisplatin in the rat. Life Sci 2007; 81: 468-479.
94. Authier N, Gillet JP, Fialip J, Eschalier A, Coudore F. An animal model of nociceptive peripheral neuropathy following repeated cisplatin injections. Exp Neurol 2003; 182:12-20.
95. Pascual D, Goicoechea C, Suardíaz M, Martín MI. A cannabinoid agonist, WIN 55,212-2, reduces neuropathic nociception induced by paclitaxel in rats. Pain 2005; 118: 23-34.
96. Ibrahim MA, Ashour OM, Ibrahim YF, El-Bitar HI, Gomaa W, Abdel-Rahim SR. Angiotensin-converting enzyme inhibition and angiotensin AT(1)-receptor antagonism equally improve doxorubicininduced cardiotoxicity and nephrotoxicity. Pharmacol Res 2009; 60: 373-381.
97. Hydock DS, Lien CY, Hayward R. Anandamide preserves cardiac function and geometry in an acute doxorubicin cardiotoxicity rat model. J Cardiovasc Pharmacol Ther 2009; 14: 59-67.
98. Iqbal M, Dubey K, Anwer T, Ashish A, Pillai KK. Protective effects of telmisartan against acute doxorubicin-induced cardiotoxicity in rats. Pharmacol Rep 2008; 60: 382-390.
99. Andreadou I, Sigala F, Iliodromitis EK, et al. Acute doxorubicin cardiotoxicity is successfully treated with the phytochemical oleuropein through suppression of oxidative and nitrosative stress. J Mol Cell Cardiol 2007; 42: 549-558.
100. Adamson IY. Pulmonary toxicity of bleomycin. Environ Health Perspect 1976; 16: 119-125.
101. Doll DC, Yarbro JW. Vascular toxicity associated with antineoplastic agents. Semin Oncol 1992; 19: 580-596.
102. Hansen SW, Olsen N, Rossing N, Rorth M. Vascular toxicity and the mechanism underlying Raynaud's phenomenon in patients treated with cisplatin, vinblastine and bleomycin. Ann Oncol 1990; 1: 289-292.
103. Harrell RM, Sibley R, Vogelzang NJ. Renal vascular lesions after chemotherapy with vinblastine, bleomycin,and cisplatin. Am J Med 1982; 73: 429-433.
104. St Croix B, Rago C, Velculescu V, et al. Genes expressed in human tumor endothelium. Science 2000; 289: 1197-1202.
105. Gerl A. Vascular toxicity associated with chemotherapy for testicular cancer. Anticancer Drugs 1994; 5: 607-614.
106. Goldhirsch A, Joss R, Markwalder TM, Studer H, Brunner K. Acute cerebrovascular accident after treatment with cisplatinum and methylprednisolone. Oncology 1983; 40: 344-345.
107. Brouha ME, Bloemendal HJ, Kappelle LJ, Winter JB. Cerebral infarction and myocardial infarction due to cisplatin-containing chemotherapy. Ned Tijdschr Geneeskd 2003; 147: 457-460.
108. Vogelzang NJ, Bosl GJ, Johnson K, Kennedy BJ. Raynaud's phenomenon: a common toxicity after combination chemotherapy for testicular cancer. Ann Intern Med 1981; 95: 288-292.
109. Licciardello JT, Moake JL, Rudy CK, Karp DD, Hong WK. Elevated plasma von Willebrand factor levels and the arterial occlusive complications associated with cisplatin-based chimiotherapy. Oncology 1985; 42: 296-300.
110. De Forni M, Malet-Martino MC, Jaillais P, et al. Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol 1992; 10: 1795-1801.
111. Dursun B, He Z, Somerset H, Oh DJ, Faubel S, Edelstein CL. Caspases and calpain are independent mediators of cisplatininduced endothelial cell necrosis. Am J Physiol Renal Physiol 2006; 291: 578-587.
112. Boulanger CM, Amabile N, Tedgui A. Circulating microparticles: a potential prognostic marker for atherosclerotic vascular disease. Hypertension 2006; 48: 180-186.
113. Amabile N, Guerin AP, Leroyer A, et al. Circulating endothelial microparticles are associated with vascular dysfonction in patient with end-stage renal failure. J Am Soc Nephrol 2005; 16: 3381-3338.
114. Lee YJ, Jy W, Horstman LL, et al. Elevated platelet microparticles in transient ischemic attacks, lacunar infarcts, and multiinfarct lacunar dementias. Thromb Res 1993; 72: 295-304.
115. Moseley PL, Hemken C, Hunninghake GW. Augmentation of fibroblast proliferation by bleomycin. J Clin Invest 1986; 78: 1150-1154.
116. Doll DC, Yarbro JW. Vascular toxicity associated with chemotherapy and hormonotherapy. Curr Opin Oncol 1994; 6: 345-350.
117. Lorenzo E, Ruiz-Ruiz C, Quesada AJ, et al. Doxorubicin induces apoptosis and CD95 gene expression in human primary endothelial cells through a p53-dependent mechanism. J Biol Chem 2002; 277: 10883-10892.
118. Meinardi MT, Gietema JA, van Veldhuisen DJ, van der Graaf WT, de Vries EG, Sleijfer DT. Long-term chemotherapyrelated cardiovascular morbidity. Cancer Treat Rev 2000; 26: 429-447.
119. Zafrani ES. Drug-induced vascular lesions of the liver. Anat Pathol 1997; 2: 135-145.
120. Miller KD, Sweeney CJ, Sledge Jr GW. Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 2001; 19: 1195-1206.